ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Decibel Therapeutics, a Boston-based biotech developing drugs for hearing loss, has launched with $52 million in its first round of funding. Third Rock Ventures led the Series A financing, with SR One, the venture arm of GlaxoSmithKline, contributing. Although approximately 50 million Americans experience some form of hearing loss, treatments are few. Decibel will target disorders including hearing loss stemming from antibiotic use, noise-induced hearing loss, age-related hearing loss, and tinnitus.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter